19.49
-0.2188(-1.11%)
Currency In USD
| Previous Close | 19.71 |
| Open | 19.97 |
| Day High | 20.09 |
| Day Low | 19.35 |
| 52-Week High | 21.02 |
| 52-Week Low | 3.42 |
| Volume | 480,553 |
| Average Volume | 3.06M |
| Market Cap | 901.74M |
| PE | -6.48 |
| EPS | -3.01 |
| Moving Average 50 Days | 15.14 |
| Moving Average 200 Days | 11.63 |
| Change | -0.22 |
If you invested $1000 in UroGen Pharma Ltd. (URGN) since IPO date, it would be worth $1,394.22 as of August 18, 2025 at a share price of $19.491. Whereas If you bought $1000 worth of UroGen Pharma Ltd. (URGN) shares 5 years ago, it would be worth $858.27 as of August 18, 2025 at a share price of $19.491.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire Inc.
Aug 05, 2025 12:00 PM GMT
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a bi
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
GlobeNewswire Inc.
Jul 29, 2025 12:00 PM GMT
Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solu
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
GlobeNewswire Inc.
Jul 28, 2025 12:00 PM GMT
PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Revie